Core Viewpoint - Viatris Inc. is facing a securities class action lawsuit for failing to disclose material information during the Class Period, which has led to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who purchased Viatris securities between August 8, 2024, and February 26, 2025, have until June 3, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Western District of Pennsylvania [1]. - The case is identified as Quinn v. Viatris Inc., et al., No. 25-cv-466 [4]. Group 2: Financial Impact - On February 27, 2025, Viatris announced disappointing fiscal 2025 guidance, attributing it to the expected financial impact from an Indore facility warning letter and import alert [4]. - Following this announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, indicating a significant loss in market value [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent boutique securities litigation law firm, is representing the investors in this case [5]. - The firm has a strong track record, being ranked among the top 10 firms nationally based on total settlement value [5].

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. due to alleged misrepresentation of the impact of a warning letter from the FDA regarding its Indore, India facility, which led to a significant decline in stock price following disappointing financial results [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Viatris securities between August 8, 2024, and February 26, 2025 [1]. - The complaint claims that the defendants misrepresented the severity of the FDA's warning letter, downplaying it as a "minor headwind" for the company [2]. - Following the announcement of disappointing fiscal 2025 guidance attributed to the warning letter and import alert, Viatris' stock price fell from $11.24 to $9.53, a decline of approximately 15.21% in one day [2]. Group 2: Investor Information - Investors who acquired shares of Viatris are encouraged to contact the law firm before the lead plaintiff motion deadline on June 3, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation [3].

Viatris, Inc. (VTRS) announced that it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.Per the terms of the settlement agreement, Viatris would pay up to a maximum of $335 million to all the above-mentioned parties. This sum consists of annual payments of approximately $27.5-$40 million to each party over a period of nine years to help support state and local efforts to address opioid-related i ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form- ...

SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give ...

ATLANTA, April 07, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts regarding the impact of the FDA’s Warning Letter on Viatris’ financials. If you bought shares of Viatris between August 8, 2024 and February 26, 2025, and you suffered a significant loss on that investment, you are e ...

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Viatris and certain of its off ...

SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit. Captioned Quinn v. Viatris Inc., No. 25-cv-00466 (W.D. Pa.), the Viatris class action lawsuit charges Viatris and certain of Viatris’ top executives with viola ...

Core Viewpoint - Viatris Inc. has reached a nationwide settlement framework to resolve opioid-related claims, agreeing to pay up to $335 million over nine years to support state and local efforts addressing opioid issues, while maintaining that this settlement does not imply any admission of wrongdoing or liability [1][2]. Group 1: Settlement Details - The settlement amount could reach a maximum of $335 million, with annual payments ranging from approximately $27.5 million to $40 million over a nine-year period [2]. - The company had already accrued an estimate for this potential settlement, which is reflected in its annual report for the year ended December 31, 2024 [2]. Group 2: Commitment to Public Health - The company continues to work on solutions for public health challenges, including manufacturing a generic injectable version of naloxone, a drug for overdose reversal, and a generic buprenorphine/naloxone product for opioid addiction treatment [3]. - Viatris is also developing a novel delivery method for meloxicam, a non-opioid pain medication [3]. Group 3: Company Mission and Operations - The settlement allows the company to focus on its mission of empowering people to live healthier lives and to address unmet patient needs through an expanded innovative portfolio [4]. - Viatris serves approximately 1 billion patients annually with its diverse portfolio of medicines, emphasizing its commitment to global healthcare [4][5].

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for alleged violations of federal securities laws related to misleading information about the company's operations and regulatory issues [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Viatris securities between August 8, 2024, and February 26, 2025, inclusive [2]. - The Complaint alleges that Viatris misrepresented the impact of a warning letter issued by the FDA regarding its Indore, India facility, downplaying it as a "minor headwind" [3]. Group 2: Next Steps - Investors who suffered losses in Viatris have until June 3, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered significant amounts for investors [6].